Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
2161-2180 of 2,251 trials

Breast Cancer Prevention: Exemestane vs. Tamoxifen

We are comparing two low-dose medications for post-menopausal women at high risk for breast cancer to see which one may improve quality of life and hormonal balance. This study aims to understand their effects over 12 months.

Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Bladder Cancer: EMDA-MMC Treatment Study

We are evaluating a new treatment using electric current to deliver mitomycin C for high-grade non-muscle invasive bladder cancer. This study compares its effectiveness and safety to the standard BCG therapy.

Non-Muscle Invasive Bladder Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesOncologyUrology

Small-Cell Lung Cancer: Tarlatamab Combination Study

We are testing a new treatment combining tarlatamab with durvalumab, carboplatin, and etoposide for patients with untreated extensive stage small-cell lung cancer. The goal is to see if this combination helps improve survival compared to standard treatment.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Breast Cancer Treatment: Elacestrant Study

We are studying whether Elacestrant alone is as effective as Elacestrant with ovarian function suppression in premenopausal women with early-stage ER+/HER2- breast cancer. The trial also looks at the safety of these treatment options.

Breast Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

CEB-01 for Pediatric Abdominal Tumors

We are testing a new treatment for children with certain types of abdominal tumors to see if it is safe and effective alongside standard care. This study focuses on children from birth to under 18 years old.

Desmoplastic Small Round Cell TumorFibrolamellar Hepatocellular CarcinomaExtracranial Malignant Rhabdoid Tumor6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesOncologyPediatrics

Psoriasis in Children: IDP-122 Lotion Study

We are testing a new lotion for children with moderate to severe plaque psoriasis to see how safe it is and how well it is absorbed into the body. This study will help us understand its effects on children's hormonal systems.

Plaque Psoriasis≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatologyEndocrinology

Clonidine for Preventing Agitation in Young Children After Anesthesia

We are studying whether clonidine can help reduce agitation and pain in children under one year after surgery. The trial also examines its safety and effects on nausea and opioid use.

Postoperative Agitation≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOtolaryngologyPediatrics

Stem Cell Transplant: New T Cell Therapy

We are studying a new treatment using special T cells to help prevent complications in patients receiving stem cell transplants from siblings. The goal is to see if this approach can safely reduce the need for other medications.

Healthy Participants6-12 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyInfectious DiseasesInternal Medicine

Lung Cancer: Nivolumab with Ipilimumab and Chemotherapy

We are studying a new way to administer nivolumab alongside ipilimumab and chemotherapy for patients with untreated metastatic or recurrent lung cancer. The trial aims to understand how the body reacts to this combination and its safety.

Non-small cell lung cancer6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Hairy Cell Leukemia: Vemurafenib and Rituximab Study

We are exploring a new treatment combination for hairy cell leukemia that may be less toxic than standard chemotherapy. This study aims to see if it is just as effective while monitoring patient safety and quality of life.

Hairy Cell Leukaemia>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Hodgkin Lymphoma: Ruxolitinib with Brentuximab or Pembrolizumab

We are studying the combination of ruxolitinib with either brentuximab or pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma. The goal is to see if this combination improves treatment response and safety.

Recurrent or Refractory Classical Hodgkin Lymphoma3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Prostate Cancer: JSB462 and Lutetium Combination Study

We are studying a new treatment combining JSB462 with lutetium for adult men with advanced prostate cancer. The goal is to see how well this combination works and its safety compared to standard treatment.

Metastatic Castration-Resistant Prostate Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Ravulizumab for Pediatric IgA Nephropathy

We are studying how Ravulizumab works in children with Primary Immunoglobulin A Nephropathy. This research may help us understand its effects and safety in younger patients.

Immunoglobulin A Nephropathy6-12 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNephrologyPediatrics

Ovarian Cancer: Sentinel Lymph Node Technique Study

We are evaluating a new technique to detect lymph node spread in early-stage ovarian cancer patients. This study aims to see how well it works compared to traditional methods.

Ovarian Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Breast Cancer Treatment: Sac-TMT vs. Standard Chemotherapy

We are studying a new treatment for high-risk early-stage breast cancer to see if it works better than standard chemotherapy combined with pembrolizumab. This trial is for individuals with triple-negative or hormone receptor-low positive breast cancer.

Triple Negative Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Ulcerative Colitis: Testing OD-07656

We are studying a new treatment called OD-07656 for people with moderately to severely active ulcerative colitis. The trial aims to evaluate its safety and effectiveness compared to another therapy.

Ulcerative ColitisEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyInternal Medicine

Knee Replacement Surgery: Local Anesthetic Comparison

We are studying whether using 20 mL of local anesthetic instead of 10 mL during a nerve block can reduce opioid use and improve pain management after knee surgery.

Postoperative Pain After Knee Surgery≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOrthopedics and TraumatologyOtolaryngology

Cholangiocarcinoma: Ivosidenib Maintenance Therapy

We are studying whether the drug ivosidenib can help patients with mIDH1 cholangiocarcinoma after standard chemotherapy. The trial will also look at its safety and effects on quality of life.

Cholangiocarcinoma Treatment>2 yearsEfficacy phase (II)Confirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

TAILORED-PROM: Personalized Treatment for Preterm Premature Rupture of Membranes

We are studying if a customized antibiotic and steroid therapy can help prolong pregnancy and improve outcomes for mothers and newborns. This approach may reduce unnecessary antibiotic use compared to standard treatments.

Preterm Premature Rupture of Membranes>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsInfectious Diseases

Bipolar-I Disorder: Long-term Safety of KarXT

We are studying the long-term safety and tolerability of KarXT for people experiencing manic episodes in Bipolar-I Disorder. This trial aims to ensure that the treatment is safe for those affected.

Mania and Bipolar DisorderConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPsychiatry